Author:
Buyse M.,Hurvitz S.A.,Andre F.,Jiang Z.,Burris H.A.,Toi M.,Eiermann W.,Lindsay M.-A.,Slamon D.
Funder
Novartis Pharmaceuticals Corporation
Reference13 articles.
1. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial;Hurvitz;Lancet Oncol,2015
2. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial;André;Lancet Oncol,2014
3. A step towards a HER2-positive breast cancer super family;Von Minckwitz;Lancet Oncol,2015
4. Statistical Methods for Research Workers;Fisher,1925
5. Statistical errors;Nuzzo;Nature,2014
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献